Comparison of clinical features between the patients with MOG-ON and AQP4-ON
| MOG-ON | AQP4-ON | P value | |
| Number of patients (N) | 20 | 45 | |
| Number of affected eyes (N, %) | 34/40, 68 | 75/90, 83.3 | 0.812* |
| Recurrent ON onset (N, %) | 10/20, 50 | 32/45, 71.1 | 0.100* |
| Times of ON attacks ≥3 (N, %) | 6/20, 30 | 18/45, 40 | 0.441* |
| Time of first to second attack (months, mean±SD) | 28.6±30.1 | 31.1±35.3 | 0.842† |
| Bilateral ON at first ON attack (N, %) | 9/20, 45 | 17/45, 37.8 | 0.583* |
| Optic nerve head swelling (N, %) | 16/20, 80 | 9/45, 20 | <0.001* |
| Severe visual loss (<0.1) at onset, number of eyes (N, %) | 22/40, 55 | 36/90, 40 | 0.112* |
| Severe visual loss (<0.1) at Nadir, number of eyes (N, %) | 27/40, 67.5 | 64/90, 71.1 | 0.678* |
| Severe visual loss (<0.1) at latest follow-up, number of eyes (N, %) | 8/40, 20 | 42/90, 46.7 | 0.004* |
*Pearson χ2 test.
†Independent t-test.
AQP4-ON, aquaporin-4 antibody-associated ON; ON, optic neuritis; MOG-ON, myelin oligodendrocyte glycoprotein antibody-associated ON.